- Libo Pharma Corp. – Founded in 2017, focused on unmet medical needs.
- Lead asset: NM-IL-12, a first-in-class cytokine immunotherapy.
- Received Orphan Drug Designation (ODD) from EMA and FDA.
- Completed EOP2 meeting and initiating pivotal trial for cutaneous T cell Lymphoma (CTCL).
- Over 200 patients dosed, showing well tolerated safety.
- NM-IL-12 is under development for cutaneous T cell Lymphoma (CTCL), Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS) and Diffused Large B Cell Lymphoma(DLBCL).
Address
Taipei City
Taiwan
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}